Endoxifen - Atossa genetics

Drug Profile

Endoxifen - Atossa genetics

Latest Information Update: 05 Jun 2017

Price : $50

At a glance

  • Originator Atossa Genetics
  • Class Antineoplastics; Methylamines; Phenyl ethers; Stilbenes
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 05 Jun 2017 Chemical structure information added
  • 19 May 2017 Atossa Genetics completes enrolment in its phase I trial for Breast cancer (Topical) in Australia
  • 10 May 2017 Independent Safety Committee gives second recommendation for advancement of endoxifen to final dosing level in a phase I trial for Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top